Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc (GSK) covers the month of September 2019. The report serves as a notification to the market regarding the Company's total voting rights and capital structure in conformity with the Financial Conduct Authority's Disclosure Guidance and Transparency Rule 5.6.1R.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This document is strictly a capital structure notification and does not contain financial performance data.
Material Changes
The filing details the Company's issued share capital as of August 30, 2019:
- Total Issued Shares: 5,382,055,713 Ordinary Shares of 25 pence each.
- Treasury Shares: 393,505,950 Ordinary Shares held in Treasury.
- Total Voting Rights: 4,988,549,763.
No material changes to financial performance or operational status are reported in this document.
Guidance, Outlook, and Risks
The filing text does not provide a clear value for guidance, outlook, management commentary, risks, contingencies, or unusual items. The document's sole purpose is to establish the denominator for shareholder notification calculations under FCA rules.
Investor Verification Checklist
- Verify the total number of voting rights (4,988,549,763) for compliance with FCA disclosure thresholds.
- Confirm the number of shares held in Treasury (393,505,950) to calculate the net outstanding share count.
- Note that this filing does not contain financial results; refer to Form 20-F or quarterly earnings releases for performance metrics.